Global Inflammatory Bowel Diseases Market, By Type (Microscopic Colitis, Ulcerative Colitis, Crohn's Disease), Treatment (Medication, Surgery, Others), Dosage Form (Tablet, Capsule, Injections, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Imaging Procedures, Endoscopic Procedures, Lab Tests), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Chronic intestinal inflammation is a feature of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. Stomach cramps, diarrhea, and gas are common symptoms. IBD flares can be managed with medications and surgery, and the condition can be put into remission. According to the Crohn's and Colitis Foundation, biologics are prescribed to about 25% of Crohn's disease patients in the United States. Further, Crohn's disease is prevalent in 319 per 100,000 people in North America and 322 per 100,000 people in Europe.
Data Bridge Market Research analyses that the inflammatory bowel diseases market was valued at USD 20.22 billion in 2021 and is expected to reach USD 30.56 billion by 2029, registering a CAGR of 5.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Million, Volumes in Units, Pricing in USD
Type (Microscopic Colitis, Ulcerative Colitis, Crohn's Disease), Treatment (Medication, Surgery, Others), Dosage Form (Tablet, Capsule, Injections, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Imaging Procedures, Endoscopic Procedures, Lab Tests), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Baxter (U.S.), Bayer AG (Germany), Eli Lilly and Company (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Allergan (Ireland), AbbVie Inc. (U.S.), Abbott (U.S.), Bausch Health Companies Inc. (Canada)
Inflammatory bowel diseases (IBD) is a collection of conditions that cause persistent inflammation (pain and swelling) in the intestines. Crohn's disease and ulcerative colitis are two forms of inflammatory bowel disease (IBD). Both types impact the digestive system. Treatments are available to assist in the management of this chronic disease. IBD treatment aims to lessen the inflammation that causes your signs and symptoms. In the best-case scenario, this could result in symptom relief and long-term remission and lowered complications risks. Drug therapy and surgery are commonly used to treat IBD. Drug therapy include the use of corticosteroids, biologics, immunosuppressant, anti-diarrheal medications, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and others.
Inflammatory Bowel Diseases Market Dynamics
- High prevalence rate of Crohn's disease and ulcerative colitis
The rising prevalence of Crohn's disease and ulcerative colitis across the globe will act as a major driver that will result in the expansion of the market's growth rate. Every year, approximately 70,000 new instances of inflammatory bowel disease are diagnosed in the United States, according to the Crohn's and Colitis Foundation (CCFA). According to a 2019 CCFA estimate, around 1.6 million people in the United States suffered from IBD. Furthermore, the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) estimates that 3.4 million people in Europe was living with IBD in 2020. IBD is affecting an increasing number of people, increasing the demand for appropriate treatment alternatives.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of the inflammatory bowel diseases market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Unhealthy lifestyle due to rapid urbanization
As the world changes, most countries are moving towards urbanization. People from various countries are significantly interested in modern culture and popular activities. People are also gravitating toward a lavish lifestyle, which has resulted in an unhealthy way of living. Additionally, the introduction of modern technologies has rendered people sluggish and inactive. People are also engaging in unhealthy behaviours such as smoking and consuming alcohol. Inflammatory bowel disease is one of the health disorders that has arisen as a result of an unhealthy lifestyle.
Furthermore, a surging number of government initiatives to spread awareness and increasing the geriatric population will result in the expansion of the inflammatory bowel diseases market. Along with this, rising level of disposable income and growing government favourable initiatives will enhance the market's growth rate.
- Increase in the number of clinical trials
The market's growth is fueled by an increase in the number of clinical trials. This will provide beneficial opportunities for the inflammatory bowel diseases market growth. According to the US National Library of Medicine, there are 730 clinical trials (including medication development, observational studies, and others) connected to IBD as of October 2019, with 268 clinical trials being undertaken just in the United States. There are 63 phase-1 clinical trials, 132 phase-2 clinical trials, and 101 phase-3 clinical trials in the inflammatory bowel disease area of drug development worldwide. Rinvoq (upadacitinib), a JAK inhibitor developed by AbbVie Inc., is a promising therapeutic candidate in phase 3 clinical trials for the treatment of Crohn's disease and ulcerative colitis. Companies are working on JAK inhibitors, anti-interleukin, S1P modulators, and other biologics to treat IBD.
- Surging approval of biosimilars
Due to the advantages of biosimilars such as Hyrimoz, Renflexis, Imraldi and Inflectra over traditional treatment choices, the adoption of effective treatment is projected to expand. Other biosimilars, such as Avsola (Amgen Inc.), Cyltezo (Boehringer Ingelheim), IXIFI (Pfizer Inc.) and Hulio (Mylan N.V.) have been approved and will be launched soon. Because emerging markets are price sensitive, the introduction of biosimilars is projected to enhance demand. Also contributing to worldwide market growth will be the rising approval of biosimilars for pediatric Crohn's disease.
Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the inflammatory bowel diseases market growth.
On the other hand, the high cost associated with the treatment will obstruct the growth rate of inflammatory bowel diseases market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and a strict regulatory scenario will challenge the market's inflammatory bowel diseases. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This inflammatory bowel diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the inflammatory bowel diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Inflammatory bowel diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
- In September 2021, AzurRx BioPharma announced the acquisition of First Wave Bio and its Proprietary Niclosamide Formulations targeting multi-billion dollar inflammatory bowel disease indications. First Wave Bio is a clinical-stage biotechnology firm focused on developing innovative, gut-targeted small molecule therapeutics for auto-immune inflammatory bowel disorders (IBD) and other severe diseases. Niclosamide is a prescription small molecule medication that the World Health Organization considers to be an essential medicine (WHO). Millions of patients have safely utilized niclosamide for a variety of therapeutic indications.
Global Inflammatory Bowel Diseases Market Scope
The inflammatory bowel diseases market is segmented on the basis of type, dosage form, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Microscopic Colitis
- Ulcerative Colitis
- Crohn's Disease
- Anti-diarrheal Medications
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Imaging Procedures
- Magnetic resonance imaging (MRI)
- Computerized tomography (CT) scan
- Endoscopic Procedures
- Balloon-assisted enteroscopy
- Capsule endoscopy
- Upper endoscopy
- Flexible sigmoidoscopy
- Lab Tests
- Stool studies
- Tests for anemia or infection
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Inflammatory Bowel Diseases Market Regional Analysis/Insights
The inflammatory bowel diseases market is analysed and market size insights and trends are provided by country, type, dosage form, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the inflammatory bowel diseases market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the inflammatory bowel diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing demand for a specific treatment, and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, presence of major key players and high prevalence of inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to growing level of disposable income in this region. Also, the development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Inflammatory Bowel Diseases Market Share Analysis
The inflammatory bowel diseases market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to inflammatory bowel diseases market.
Some of the major players operating in the inflammatory bowel diseases market are:
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Baxter (U.S.)
- Bayer AG (Germany)
- Eli Lilly and Company (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Allergan (Ireland)
- AbbVie Inc. (U.S.)
- Abbott (U.S.)
- Bausch Health Companies Inc. (Canada)